PL2540309T3 - Peptydy chroniące tkanki i ich zastosowanie - Google Patents

Peptydy chroniące tkanki i ich zastosowanie

Info

Publication number: PL2540309T3
Authority: PL; Poland
Prior art keywords: tissue protective; protective peptides; peptides; tissue; protective
Prior art date: 2005-08-05

Application number

PL12175352T

Other languages

English (en)

Inventor

Anthony Cerami

Michael Brines

Thomas Coleman

Original Assignee

Araim Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-08-05

Filing date

2006-08-07

Publication date

2018-03-30

2006-08-07 Application filed by Araim Pharmaceuticals, Inc. filed Critical Araim Pharmaceuticals, Inc.

2018-03-30 Publication of PL2540309T3 publication Critical patent/PL2540309T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Immunology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cell Biology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Obesity (AREA)

PL12175352T 2005-08-05 2006-08-07 Peptydy chroniące tkanki i ich zastosowanie PL2540309T3 (pl)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US70574105P	2005-08-05	2005-08-05
US70627605P	2005-08-08	2005-08-08
US83173706P	2006-07-18	2006-07-18
EP11163194.1A EP2371855B1 (en)	2005-08-05	2006-08-07	Tissue protective peptides and uses thereof
EP06801051A EP1924276A4 (en)	2005-08-05	2006-08-07	Antiperspirant peptides and their uses
EP12175352.9A EP2540309B1 (en)	2005-08-05	2006-08-07	Tissue protective peptides and uses thereof

Publications (1)

Publication Number	Publication Date
PL2540309T3 true PL2540309T3 (pl)	2018-03-30

Family

ID=37728020

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL12175352T PL2540309T3 (pl)	2005-08-05	2006-08-07	Peptydy chroniące tkanki i ich zastosowanie
PL12175366T PL2594279T3 (pl)	2005-08-05	2006-08-07	Peptydy chroniące tkanki i ich zastosowania
PL11163194T PL2371855T3 (pl)	2005-08-05	2006-08-07	Peptydy o działaniu ochronnym wobec tkanek

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
PL12175366T PL2594279T3 (pl)	2005-08-05	2006-08-07	Peptydy chroniące tkanki i ich zastosowania
PL11163194T PL2371855T3 (pl)	2005-08-05	2006-08-07	Peptydy o działaniu ochronnym wobec tkanek

Country Status (25)

Country	Link
US (7)	US8071554B2 (pl)
EP (5)	EP1924276A4 (pl)
JP (6)	JP5274253B2 (pl)
KR (7)	KR101713368B1 (pl)
CN (2)	CN103724418B (pl)
AU (1)	AU2006278264B2 (pl)
BR (1)	BRPI0614529A8 (pl)
CA (3)	CA2618396C (pl)
DK (3)	DK2371855T3 (pl)
EA (1)	EA015672B1 (pl)
ES (3)	ES2653790T3 (pl)
HU (3)	HUE035793T2 (pl)
IL (3)	IL189287A (pl)
IN (1)	IN2014CN02050A (pl)
LT (2)	LT2594279T (pl)
MX (3)	MX2008001509A (pl)
NO (1)	NO20081112L (pl)
NZ (1)	NZ565937A (pl)
PL (3)	PL2540309T3 (pl)
PT (3)	PT2540309T (pl)
SG (2)	SG10201805825SA (pl)
SI (3)	SI2371855T1 (pl)
UA (1)	UA100222C2 (pl)
WO (1)	WO2007019545A2 (pl)
ZA (1)	ZA201101890B (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030072737A1 (en) *	2000-12-29	2003-04-17	Michael Brines	Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US9345745B2 (en) *	2005-04-29	2016-05-24	Bo Wang	Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US9585932B2 (en) *	2005-04-29	2017-03-07	Peter C. Dowling	Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
US8653028B2 (en) *	2005-04-29	2014-02-18	Rui Rong Yuan	Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
SI2371855T1 (sl)	2005-08-05	2015-11-30	Araim Pharmaceuticals, Inc.	Peptidi, ki ščitijo tkiva, in načini njihove uporabe
WO2007142288A1 (ja) *	2006-06-07	2007-12-13	The University Of Tokushima	エリスロポエチンを用いた虚血性疾患の治療
EP2081956B1 (en)	2006-11-13	2013-03-20	Charité - Universitätsmedizin Berlin	Method of cell culture and method of treatment comprising a vepo protein variant
NZ621196A (en) *	2008-01-22	2015-08-28	Araim Pharmaceuticals Inc	Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
AU2016203452B2 (en) *	2008-01-22	2018-02-22	Araim Pharmaceuticals, Inc.	Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
AU2014203195B2 (en) *	2008-01-22	2016-03-31	Araim Pharmaceuticals, Inc.	Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
WO2012051581A2 (en) *	2010-10-14	2012-04-19	Rutgers, The State University Of New Jersey	Intestinal peptide targeting ligands
US9566349B2 (en) *	2010-10-14	2017-02-14	Rutgers, The State University Of New Jersey	Intestinal peptide targeting ligands
CN102180948A (zh) *	2011-03-03	2011-09-14	复旦大学附属中山医院	一种具有肾脏保护作用的短肽及其制备方法和应用
CN102212111B (zh) *	2011-05-05	2014-04-30	中国人民解放军第三军医大学	小分子多肽和小分子多肽脂质体及其运用
EP2736530B1 (en) *	2011-07-27	2018-06-06	Neumedicines, Inc	Use of il-12 to generate endogenous erythropoietin
WO2013042118A1 (en) *	2011-09-20	2013-03-28	A.A. Cash Technology Ltd	Methods and devices for occluding blood flow to an organ
KR101148191B1 (ko) *	2011-09-27	2012-05-23	김후정	에리스로포이에틴-유래 펩타이드 및 그 용도
WO2013158871A1 (en) *	2012-04-20	2013-10-24	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Use of erythropoietin and derivatives for treating hypertension
KR20160052537A (ko) *	2013-07-17	2016-05-12	아라임 파마슈티칼즈, 인크.	조직 손상과 연관된 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
CN104744593A (zh) *	2013-12-25	2015-07-01	深圳先进技术研究院	一种抗肿瘤血管生成免疫复合肽及其制备方法和应用
US11039621B2 (en)	2014-02-19	2021-06-22	Corning Incorporated	Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039620B2 (en)	2014-02-19	2021-06-22	Corning Incorporated	Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en)	2014-02-19	2017-04-18	Corning Incorporated	Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
KR20150130616A (ko) *	2014-05-13	2015-11-24	(주)케어젠	피부상태 개선 활성을 갖는 펩타이드 및 이의 용도
CN105968172A (zh) *	2014-06-22	2016-09-28	马恒标	组织保护活性多肽sl2及其应用
SG11201802777XA (en) *	2015-10-14	2018-05-30	X Therma Inc	Compositions and methods for reducing ice crystal formation
EP3448415A4 (en)	2016-04-29	2019-11-06	Araim Pharmaceuticals, Inc.	TREATMENT-PROOFING PEPTIDES FOR THE PREVENTION AND TREATMENT OF DISEASES AND DISORDERS RELATED TO TISSUE DAMAGE
AU2017357374B2 (en)	2016-11-10	2023-05-18	Asc Regenity Ltd.	Cosmetic formulations for topical applications containing erythropoietin-derived molecules
KR101965814B1 (ko)	2017-02-27	2019-08-13	재단법인 대구경북과학기술원	에리스로포이에틴 유래 펩티드의 세포손상방지에 효과를 통한 활용
US11260101B2 (en)	2017-02-28	2022-03-01	Jinan University	Repair peptide for use in promoting post-traumatic tissue repair and regeneration, and application thereof
CN108503690B (zh) *	2017-02-28	2020-07-03	暨南大学	一种促进创伤后组织修复与再生的修复肽及其应用
JP7481261B2 (ja) *	2018-04-08	2024-05-10	ブリムバイオテクノロジーインク	腱治癒に対するｐｅｄｆ由来短鎖ペプチドの使用
KR102300060B1 (ko)	2018-06-12	2021-09-08	주식회사 엘지에너지솔루션	2열 터미널 구조의 pcb 다이렉트 커넥터
WO2020055768A1 (en)	2018-09-10	2020-03-19	Cold Spring Harbor Laboratory	Methods for treating pancreatitis
CN112390877B (zh) *	2019-08-16	2022-10-04	董红燕	Pedf衍生多肽组合物及其在制备保护肺损伤药物中的应用
CN118255845B (zh) *	2022-12-27	2025-07-11	上海瑞吉康生物医药有限公司	相分离逆转多肽的变体及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO812612L (no)	1980-08-06	1982-02-08	Ferring Pharma Ltd	Enzym-inhibitorer.
US4558006A (en) *	1983-02-04	1985-12-10	Kirin-Amgen, Inc.	A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
US5051448A (en)	1984-07-24	1991-09-24	The Mclean Hospital Corporation	GABA esters and GABA analog esters
US4704355A (en)	1985-03-27	1987-11-03	New Horizons Diagnostics Corporation	Assay utilizing ATP encapsulated within liposome particles
US4798824A (en)	1985-10-03	1989-01-17	Wisconsin Alumni Research Foundation	Perfusate for the preservation of organs
US5498694A (en)	1989-05-25	1996-03-12	La Jolla Cancer Research Foundation	Peptides of the cytoplasmic domain of integrin
DE3924746A1 (de)	1989-07-26	1991-01-31	Behringwerke Ag	Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
AU6501390A (en)	1989-09-21	1991-04-18	Synergen, Inc.	Method for transporting compositions across the blood brain barrier
US5192746A (en)	1990-07-09	1993-03-09	Tanabe Seiyaku Co., Ltd.	Cyclic cell adhesion modulation compounds
WO2004031211A2 (en) *	2002-10-03	2004-04-15	Epimmune Inc.	Hla binding peptides and their uses
US6140120A (en) *	1993-02-12	2000-10-31	Board Of Trustees Of Leland Stanford Jr. University	Regulated transcription of targeted genes and other biological events
US5559103A (en)	1993-07-21	1996-09-24	Cytel Corporation	Bivalent sialyl X saccharides
US5571787A (en)	1993-07-30	1996-11-05	Myelos Corporation	Prosaposin as a neurotrophic factor
US5700909A (en)	1993-07-30	1997-12-23	The Regents Of The University Of California	Prosaposin and cytokine-derived peptides
WO1995021919A2 (en) *	1994-02-14	1995-08-17	Kirin Brewery Company, Limited	Protein having tpo activity
ITFI940106A1 (it) *	1994-05-27	1995-11-27	Menarini Ricerche Sud Spa	Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
US5576423A (en)	1994-12-02	1996-11-19	Schering Corporation	Antibodies to the slam protein expressed on activated T cells
KR100459984B1 (ko) *	1995-06-07	2005-06-20	아피맥스 테크놀로지스, 엔.브이.	에리트로포이에틴수용체(epo-r)에결합하는화합물및펩티드
AU4267297A (en) *	1997-09-11	1998-09-22	Regents Of The University Of California, The	Method of alleviating neuropathic pain
US7153943B2 (en) *	1997-07-14	2006-12-26	Bolder Biotechnology, Inc.	Derivatives of growth hormone and related proteins, and methods of use thereof
US7270809B2 (en) *	1997-07-14	2007-09-18	Bolder Biotechnology, Inc.	Cysteine variants of alpha interferon-2
TR200103785T2 (tr)	1999-04-13	2002-06-21	The Kenneth S. Warren Institute, Inc.	Uyarılabilir doku işlevinin periferik olarak uygulanan eritropoietin vasıtasıyla düzenlenmesi
AU2001252650A1 (en) *	2000-04-28	2001-11-12	Effector Cell Institute	Novel derivative of cell chemotactic factor
JP4656814B2 (ja) *	2000-12-20	2011-03-23	エフ．ホフマン−ラロシュアーゲー	エリスロポエチンコンジュゲート
PA8536201A1 (es) *	2000-12-29	2002-08-29	Kenneth S Warren Inst Inc	Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US20030072737A1 (en)	2000-12-29	2003-04-17	Michael Brines	Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
MXPA03006990A (es)	2001-02-06	2003-11-18	Merck Patent Gmbh	Eritropoyetina (epo) modificada con inmunogenicidad reducida.
DE60232870D1 (de) *	2001-04-04	2009-08-20	Genodyssee	Neue polynukleotide und polypeptide des erythropoietingens
KR100467751B1 (ko) *	2001-12-03	2005-01-24	씨제이 주식회사	생체내 에리스로포이에틴 활성이 증진된 융합단백질
US7300915B2 (en) *	2002-06-05	2007-11-27	The Regents Of The University Of California	Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain
EA010200B1 (ru)	2002-07-01	2008-06-30	Дзе Кеннет С. Уоррен Инститьют, Инк.	Рекомбинантные тканезащитные цитокины и кодирующие их нуклеиновые кислоты для защиты, восстановления и усиления чувствительных клеток, тканей и органов
KR100478455B1 (ko)	2002-08-19	2005-03-22	삼성전자주식회사	전자렌지
EP1545586A4 (en)	2002-09-09	2007-09-26	Warren Pharmaceuticals Inc	LONG-ACTING ERYTHROPOIETINES THAT MAINTAIN THE PROTECTIVE ACTIVITY OF THE TISSUE OF ENDOGENEURY ERYTHROPOIETIN
JP2004305006A (ja) *	2003-04-01	2004-11-04	Japan Science & Technology Agency	人工調製肺サーファクタント
DE602004029349D1 (de) *	2003-04-25	2010-11-11	Univ Pittsburgh	Von muskeln stammende zellen (mdcs) zur förderung und verbesserung der nervenreparatur und -regeneration
US7718363B2 (en)	2003-04-25	2010-05-18	The Kenneth S. Warren Institute, Inc.	Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
BRPI0409650A (pt)	2003-09-09	2006-04-25	Warren Pharmaceuticals Inc	métodos para regular o nìvel hematócrito e humanos, produtos de eritropoietina artificial, métodos para preparar um produto de eritropoietina e pra tratar anemia em pacientes em risco de dano no tecido, e, composição farmacêutica
AU2004277954A1 (en)	2003-09-29	2005-04-14	The Kenneth S Warren Institute, Inc.	Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
US20080227696A1 (en) *	2005-02-22	2008-09-18	Biosurface Engineering Technologies, Inc.	Single branch heparin-binding growth factor analogs
WO2007010552A2 (en)	2005-03-17	2007-01-25	Serum Institute Of India Limited	N- terminal peg conjugate of erythropoietin
US9345745B2 (en)	2005-04-29	2016-05-24	Bo Wang	Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US8653028B2 (en)	2005-04-29	2014-02-18	Rui Rong Yuan	Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
EP2385061A3 (en)	2005-05-10	2012-02-22	Neoloch Aps	Neuritogenic peptides
EP1736481A1 (en)	2005-05-13	2006-12-27	Charite Universitätsmedizin-Berlin	Erythropoietin variants
WO2006127910A2 (en)	2005-05-25	2006-11-30	Neose Technologies, Inc.	Glycopegylated erythropoietin formulations
SI2371855T1 (sl)	2005-08-05	2015-11-30	Araim Pharmaceuticals, Inc.	Peptidi, ki ščitijo tkiva, in načini njihove uporabe
EP2109690B9 (en)	2007-11-29	2012-10-24	MOLECULAR HEALTH GmbH	Eph-b4 specific sirna for reducing epo-induced tumor cell growth during anemia treatment in cancer patients, tissue protective erythropoietin receptor (nepor) and methods of use.
NZ621196A (en)	2008-01-22	2015-08-28	Araim Pharmaceuticals Inc	Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
JP2011523353A (ja) *	2008-04-28	2011-08-11	プレジデントアンドフェロウズオブハーバードカレッジ	細胞透過のための過剰に荷電されたタンパク質
WO2011022056A2 (en)	2009-08-18	2011-02-24	Medical College Of Georgia Research Institute, Inc.	PEPTIDE MODULATORS OF THE δPKC INTERACTION WITH THE D SUBUNIT OF F1FO ATP SYNTHASE/ATPASE AND USES THEREOF

2006
- 2006-08-07 SI SI200631979T patent/SI2371855T1/sl unknown
- 2006-08-07 PL PL12175352T patent/PL2540309T3/pl unknown
- 2006-08-07 PT PT121753529T patent/PT2540309T/pt unknown
- 2006-08-07 KR KR1020137016015A patent/KR101713368B1/ko not_active Expired - Fee Related
- 2006-08-07 HU HUE12175352A patent/HUE035793T2/en unknown
- 2006-08-07 ES ES12175366.9T patent/ES2653790T3/es active Active
- 2006-08-07 MX MX2008001509A patent/MX2008001509A/es active IP Right Grant
- 2006-08-07 EP EP06801051A patent/EP1924276A4/en not_active Withdrawn
- 2006-08-07 KR KR1020197019568A patent/KR20190084136A/ko not_active Ceased
- 2006-08-07 DK DK11163194.1T patent/DK2371855T3/en active
- 2006-08-07 DK DK12175352.9T patent/DK2540309T3/en active
- 2006-08-07 JP JP2008525285A patent/JP5274253B2/ja not_active Expired - Fee Related
- 2006-08-07 CA CA2618396A patent/CA2618396C/en not_active Expired - Fee Related
- 2006-08-07 KR KR1020187030050A patent/KR20180116475A/ko not_active Ceased
- 2006-08-07 PL PL12175366T patent/PL2594279T3/pl unknown
- 2006-08-07 HU HUE11163194A patent/HUE026444T2/en unknown
- 2006-08-07 AU AU2006278264A patent/AU2006278264B2/en not_active Ceased
- 2006-08-07 UA UAA200802850A patent/UA100222C2/uk unknown
- 2006-08-07 EP EP11163194.1A patent/EP2371855B1/en active Active
- 2006-08-07 WO PCT/US2006/031061 patent/WO2007019545A2/en not_active Ceased
- 2006-08-07 SI SI200632230T patent/SI2594279T1/en unknown
- 2006-08-07 EP EP17202352.5A patent/EP3363451A1/en not_active Withdrawn
- 2006-08-07 CA CA2982909A patent/CA2982909A1/en not_active Abandoned
- 2006-08-07 PL PL11163194T patent/PL2371855T3/pl unknown
- 2006-08-07 EP EP12175366.9A patent/EP2594279B1/en active Active
- 2006-08-07 NZ NZ565937A patent/NZ565937A/en not_active IP Right Cessation
- 2006-08-07 EA EA200800536A patent/EA015672B1/ru not_active IP Right Cessation
- 2006-08-07 IN IN2050CHN2014 patent/IN2014CN02050A/en unknown
- 2006-08-07 HU HUE12175366A patent/HUE035655T2/en unknown
- 2006-08-07 ES ES11163194.1T patent/ES2550055T3/es active Active
- 2006-08-07 MX MX2014011168A patent/MX339613B/es unknown
- 2006-08-07 LT LTEP12175366.9T patent/LT2594279T/lt unknown
- 2006-08-07 KR KR1020187016750A patent/KR20180067735A/ko not_active Ceased
- 2006-08-07 KR KR1020177005579A patent/KR20170027868A/ko not_active Ceased
- 2006-08-07 CN CN201310529242.5A patent/CN103724418B/zh not_active Expired - Fee Related
- 2006-08-07 SI SI200632233T patent/SI2540309T1/en unknown
- 2006-08-07 LT LTEP12175352.9T patent/LT2540309T/lt unknown
- 2006-08-07 CN CN2006800348244A patent/CN101378772B/zh not_active Expired - Fee Related
- 2006-08-07 CA CA3079319A patent/CA3079319A1/en not_active Abandoned
- 2006-08-07 KR KR1020087005373A patent/KR101626153B1/ko not_active Expired - Fee Related
- 2006-08-07 KR KR1020207016998A patent/KR20200072568A/ko not_active Ceased
- 2006-08-07 ES ES12175352.9T patent/ES2653864T3/es active Active
- 2006-08-07 DK DK12175366.9T patent/DK2594279T3/en active
- 2006-08-07 MX MX2016004825A patent/MX364100B/es unknown
- 2006-08-07 SG SG10201805825SA patent/SG10201805825SA/en unknown
- 2006-08-07 BR BRPI0614529A patent/BRPI0614529A8/pt not_active Application Discontinuation
- 2006-08-07 US US11/997,898 patent/US8071554B2/en not_active Expired - Fee Related
- 2006-08-07 PT PT111631941T patent/PT2371855E/pt unknown
- 2006-08-07 EP EP12175352.9A patent/EP2540309B1/en active Active
- 2006-08-07 PT PT121753669T patent/PT2594279T/pt unknown
- 2006-08-07 SG SG2014007868A patent/SG2014007868A/en unknown
2008
- 2008-02-05 IL IL189287A patent/IL189287A/en active IP Right Grant
- 2008-03-03 NO NO20081112A patent/NO20081112L/no not_active Application Discontinuation
2011
- 2011-03-11 ZA ZA2011/01890A patent/ZA201101890B/en unknown
- 2011-10-20 US US13/278,131 patent/US8716245B2/en not_active Expired - Fee Related
2012
- 2012-04-16 US US13/448,345 patent/US8673861B2/en not_active Expired - Fee Related
2013
- 2013-02-15 JP JP2013027479A patent/JP5918155B2/ja not_active Expired - Fee Related
2014
- 2014-04-08 US US14/248,030 patent/US9340598B2/en not_active Expired - Fee Related
2015
- 2015-02-04 JP JP2015020020A patent/JP6158235B2/ja not_active Expired - Fee Related
- 2015-02-10 US US14/618,873 patent/US20150152156A1/en not_active Abandoned
- 2015-06-29 IL IL239695A patent/IL239695A0/en active IP Right Grant
2016
- 2016-05-05 US US15/147,848 patent/US10100096B2/en not_active Expired - Fee Related
- 2016-06-08 JP JP2016114010A patent/JP6491621B2/ja not_active Expired - Fee Related
2018
- 2018-04-03 JP JP2018071318A patent/JP2018134084A/ja active Pending
- 2018-08-23 IL IL261346A patent/IL261346A/en unknown
- 2018-09-25 US US16/141,724 patent/US20190016769A1/en not_active Abandoned
2020
- 2020-01-30 JP JP2020013151A patent/JP2020078317A/ja active Pending

Also Published As

Publication number	Publication date
WO2007019545A3 (en)	2008-10-02
CA2982909A1 (en)	2007-02-15
PT2594279T (pt)	2017-12-29
JP2013126995A (ja)	2013-06-27
SI2371855T1 (sl)	2015-11-30
US9340598B2 (en)	2016-05-17
KR101713368B1 (ko)	2017-03-07
DK2371855T3 (en)	2015-09-21
KR101626153B1 (ko)	2016-06-01
US20090221482A1 (en)	2009-09-03
CA2618396C (en)	2018-02-27
KR20130080481A (ko)	2013-07-12
PL2371855T3 (pl)	2015-12-31
ES2653864T3 (es)	2018-02-09
KR20180067735A (ko)	2018-06-20
EP1924276A2 (en)	2008-05-28
KR20190084136A (ko)	2019-07-15
JP5918155B2 (ja)	2016-05-18
JP2016196480A (ja)	2016-11-24
EP2594279A1 (en)	2013-05-22
US20160244498A1 (en)	2016-08-25
EP2594279B1 (en)	2017-11-22
IL261346A (en)	2018-10-31
EP2540309A3 (en)	2013-05-29
CN101378772A (zh)	2009-03-04
CN101378772B (zh)	2013-12-04
AU2006278264B2 (en)	2012-12-06
EP2371855A1 (en)	2011-10-05
CN103724418A (zh)	2014-04-16
US8716245B2 (en)	2014-05-06
JP2020078317A (ja)	2020-05-28
US8673861B2 (en)	2014-03-18
ES2653790T3 (es)	2018-02-08
HK1127751A1 (en)	2009-10-09
KR20200072568A (ko)	2020-06-22
BRPI0614529A2 (pt)	2011-08-09
JP2009508471A (ja)	2009-03-05
JP2018134084A (ja)	2018-08-30
MX2008001509A (es)	2008-04-04
IL189287A (en)	2015-07-30
WO2007019545A2 (en)	2007-02-15
MX339613B (es)	2016-06-02
HUE026444T2 (en)	2016-05-30
JP2015134772A (ja)	2015-07-27
PT2540309T (pt)	2017-12-29
US20120142595A1 (en)	2012-06-07
SI2594279T1 (en)	2018-04-30
NO20081112L (no)	2008-05-05
UA100222C2 (uk)	2012-12-10
EP2540309A2 (en)	2013-01-02
US8071554B2 (en)	2011-12-06
CN103724418B (zh)	2018-03-06
KR20180116475A (ko)	2018-10-24
US20150152156A1 (en)	2015-06-04
IN2014CN02050A (pl)	2015-05-29
SG10201805825SA (en)	2018-08-30
ZA201101890B (en)	2012-12-27
KR20080064800A (ko)	2008-07-09
MX364100B (es)	2019-04-12
JP6158235B2 (ja)	2017-07-05
JP5274253B2 (ja)	2013-08-28
DK2594279T3 (en)	2018-01-08
LT2594279T (lt)	2018-01-10
EP3363451A1 (en)	2018-08-22
US20190016769A1 (en)	2019-01-17
US20120264682A1 (en)	2012-10-18
EA200800536A1 (ru)	2009-02-27
HUE035793T2 (en)	2018-05-28
IL189287A0 (en)	2008-06-05
IL239695A0 (en)	2015-08-31
EA015672B1 (ru)	2011-10-31
AU2006278264A1 (en)	2007-02-15
SG2014007868A (en)	2014-05-29
NZ565937A (en)	2011-09-30
PT2371855E (pt)	2015-11-03
KR20170027868A (ko)	2017-03-10
BRPI0614529A8 (pt)	2016-07-12
US10100096B2 (en)	2018-10-16
CA2618396A1 (en)	2007-02-15
PL2594279T3 (pl)	2018-03-30
LT2540309T (lt)	2018-01-10
SI2540309T1 (en)	2018-04-30
CA3079319A1 (en)	2007-02-15
EP2371855B1 (en)	2015-07-22
DK2540309T3 (en)	2018-01-08
EP2540309B1 (en)	2017-11-22
HUE035655T2 (en)	2018-05-28
JP6491621B2 (ja)	2019-03-27
EP1924276A4 (en)	2009-07-22
US20140323401A1 (en)	2014-10-30
ES2550055T3 (es)	2015-11-04

Publication	Publication Date	Title
IL261346A (en)	2018-10-31	Tissue protective peptides and their uses
IL187617A0 (en)	2008-03-20	Lkktet and/or lkktnt peptide compositions and methods
IL185308A0 (en)	2008-02-09	Replikin peptides and uses thereof
EP1976864A4 (en)	2010-09-01	NEW PEPTIDE AND ITS USE
IL189252A0 (en)	2008-08-07	Dihydroxyanthraquinones and their use
EP1967123A4 (en)	2016-06-08	ENDOSCOPE AND ENDOSCOPE SYSTEM
IL195525A0 (en)	2011-08-01	Replikin peptides and uses thereof
GB0516069D0 (en)	2005-09-14	Pharmaceutical and use thereof
EP1893233A4 (en)	2010-03-31	PEPTIDES AND THERAPEUTIC VACCINES
ZA200801874B (en)	2009-03-25	Antigenic peptides and their use
GB0604187D0 (en)	2006-04-12	Peptide and uses thereof
IL185575A0 (en)	2008-01-06	Benzoxazocines and their therapeutic use
IL188310A0 (en)	2008-04-13	Thrombospondin-1 derived peptides and treatment methods
GB0526120D0 (en)	2006-02-01	Therapeutic peptides
ZA200800566B (en)	2008-11-26	Therapeutic peptides and vaccines
IL192800A0 (en)	2009-02-11	Fgf2-binding peptides and uses thereof
GB0617564D0 (en)	2006-10-18	Peptides and methods
GB0517813D0 (en)	2005-10-12	Peptides and uses thereof
GB0508726D0 (en)	2005-06-08	Polypeptide, vaccine and use thereof
GB0503093D0 (en)	2005-06-01	Ricin-binding peptide and methods for use thereof
GB0612873D0 (en)	2006-08-09	Isolated peptides and uses thereof
GB0425731D0 (en)	2004-12-22	Isolated peptides and uses thereof
GB0520144D0 (en)	2005-11-09	Surgical pin protector and system
HK1116833A (en)	2009-01-02	Replikin peptides and uses thereof
GB0507566D0 (en)	2005-05-18	Skin protection